Quick Answer
Cogent Biosciences, Inc. reported Net Income Loss of -$328.94 million for the year ending 2025.
- Cogent Biosciences, Inc. showed a decrease of -28.6% in Net Income Loss from 2024 to 2025.
- This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$5.94 million | Q2 2017: -$5.86 million | Q3 2017: -$7.00 million | Q4 2017: -$6.69 million | Q1 2018: -$6.74 million | Q2 2018: -$9.02 million | Q3 2018: -$10.17 million | Q4 2018: -$8.61 million | Q1 2019: -$11.69 million | Q2 2019: -$10.52 million | Q3 2019: -$11.92 million | Q4 2019: $2.30 million | Q1 2020: -$6.09 million | Q2 2020: -$7.39 million | Q3 2020: -$49.98 million | Q1 2021: -$11.73 million | Q2 2021: -$16.55 million | Q3 2021: -$19.08 million | Q1 2022: -$30.63 million | Q2 2022: -$34.93 million | Q3 2022: -$35.06 million | Q1 2023: -$38.59 million | Q2 2023: -$44.08 million | Q3 2023: -$55.38 million | Q1 2024: -$58.35 million | Q2 2024: -$58.95 million | Q3 2024: -$70.63 million | Q1 2025: -$71.99 million | Q2 2025: -$73.53 million | Q3 2025: -$80.93 million.
- Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Net Income Loss has declined by 1,190.4%.
- Historical annual values: Fiscal year 2025: -$328.94 million | Fiscal year 2024: -$255.86 million | Fiscal year 2023: -$192.41 million | Fiscal year 2022: -$140.24 million | Fiscal year 2021: -$72.27 million | Fiscal year 2020: -$74.81 million | Fiscal year 2019: -$31.83 million | Fiscal year 2018: -$34.53 million | Fiscal year 2017: -$25.49 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: